Posted by Michael Wonder on 11 Nov 2019
SMC - November 2019 decisions
11 November 2019 - A medicine used to treat advanced breast cancer has today been accepted by the SMC for use in NHSScotland.
Ribociclib (Kisqali), used in combination with another medicine, fulvestrant, was accepted for post-menopausal women living with the most common form of advanced breast cancer following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines to treat end of life and very rare conditions.
Lenvatinib (Kisplyx) was also accepted through PACE for the treatment of advanced renal cell carcinoma in those who have been previously treated with a type of cancer medicine called a ‘vascular endothelial growth factor inhibitor’.
